Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

3 Pharma Stocks Smart Money Is Following in September

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

StockNews.com

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

Barchart

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

StockNews.com

Lilly applies for Alzheimer’s drug’s US approval after trial success

Eli Lilly & Co. said it applied for full U.S. approval of its Alzheimer’s disease drug that’s expected to compete with Eisai Co.’s Leqembi as the U.S. drugmaker revealed details of a final-stage trial at a conference in Amsterdam.

Tribune News Service

Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concern

New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening

The Independent UK

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Fortune

Read news from The Economist, FT, and more,
with one subscription

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

The Guardian - UK

Lisa Jarvis: Eli Lilly’s new weight-loss drug is even better than Ozempic

New data from an experimental drug being developed by Eli Lilly & Co. raises an intriguing question about obesity treatments: How low can the weight loss go?

Tribune News Service

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

Fortune

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

The Conversation

Eli Lilly says an experimental drug slows Alzheimer's worsening

In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35% less decline in thinking skills compared to those given a dummy drug, Lilly announced.

WEKU

‘Remarkable’ drug reduces Alzheimer’s decline, study shows

Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.

Al Jazeera

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

New Alzheimer’s drug slows cognitive decline by 35%, trial results show

Donanemab is second drug in a year to succeed in trials in what could be ‘beginning of the end’ of disease

The Independent UK

Eli Lilly says experimental drug slows Alzheimer's worsening

Eli Lilly and Co. says its experimental Alzheimer's drug appears to slow worsening of the mind-robbing disease

Daily Record

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

The Independent UK

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

Get all your
news in one place.

100's of premium titles.
One news app.

Businessweek

Good Luck Paying for Those $10,000 Obesity Drugs Everyone’s Talking About

Ozempic, Wegovy and Mounjaro can cause dramatic weight loss, and could create a market worth $150 billion a year.

ABC News

Why EV conversions could become more mainstream for classic cars through to 4WD utes

From classic cars to 4WD utes, Noah Wasmer wants EV conversions to become mainstream.

Los Angeles Times

Michael Hiltzik: Eli Lilly is slashing insulin prices, but hold your applause

Eli Lilly & Co. played the altruism card like a champ on Mar. 1, when it announced steep price cuts on its insulin products of as much as 70%.

WEKU

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

The Independent UK

Novo Nordisk to slash insulin price by up to 75% in push for affordable diabetes treatments

The brand is the latest to plan dramatic price cuts for the diabetes drug

Tribune News Service

Why does insulin cost so much? Big Pharma isn’t the only player driving prices

Eli Lilly & Co.’s announcement that it is slashing prices for its major insulin products could make life easier for some diabetes patients while easing pressure on Big Pharma.

Inverse

This Essential Medical Treatment Could Finally Become Affordable For Everyone

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Australian Defence Force

129 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.